Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 9, 2014, Pages 2206-2211

  Shi, Qing ^a   Tebben, Andrew ^a   Dyckman, Alaric J ^a   Li, Hedy ^a   Liu, Chunjian ^a   Lin, James ^a   Spergel, Steve ^a   Burke, James R ^a   McIntyre, Kim W ^a   Olini, Gilbert C ^a   Strnad, Joann ^a   Surti, Neha ^a   Muckelbauer, Jodi K ^a   Chang, Chiehying ^a   An, Yongmi ^a   Cheng, Lin ^a   Ruan, Qian ^a   Leftheris, Katerina ^a   Carter, Percy H ^a   Tino, Joseph ^a   De Lucca, George V ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Autoimmune diseases; BTK; Purine

Indexed keywords

ANILINE; BENZENE; BRUTON TYROSINE KINASE INHIBITOR; CD86 ANTIGEN; PURINE DERIVATIVE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; RAT; ANIMAL CELL; AREA UNDER THE CURVE; CELL SURFACE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG OXIDATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TRANSFORMATION; ELIMINATION HALF-LIFE; ENZYME INHIBITOR INTERACTION; EXPERIMENTAL MODEL; HUMAN CELL; IC50; IN VIVO STUDY; LIPOPHILICITY; LIVER MICROSOME METABOLISM; LYMPHOCYTE PROLIFERATION; MAXIMUM PLASMA CONCENTRATION; REACTION OPTIMIZATION;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE; MODELS, MOLECULAR; PASSIVE CUTANEOUS ANAPHYLAXIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PURINES; RATS;

EID: 84899129860     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.02.075     Document Type: Article

References (26)

1. A. Mohamed, L. Yu, C. Bäckesjö, L. Vargas, R. Faryal, A. Aints, B. Christensson, A. Berglöf, M. Vihinen, B.F. Nore, and C.I.E. Smith Immunol. Rev. 228 2009 58
2. C. Mao, M. Zhou, and F.M. Uckun J. Biol. Chem. 276 2001 41435
3. M. Dinh, D. Grunberger, H. Ho, S.Y. Tsing, D. Shaw, S. Lee, J. Barnett, R.J. Hill, D.C. Swinney, and J.M. Bradshaw J. Biol. Chem. 282 2007 8768
4. M. de Weers, M.C. Verschuren, M.E. Kraakman, R.K. Schuurman, J.J. van Dongen, and R.W. Hendriks Eur. J. Immunol. 23 1993 3109
5. J. Jongstra-Bilen, C. Puig Cano, M. Hasija, H. Xiao, C.I. Smith, and M.I. Cybulsky J. Immunol. 181 2008 288
6. H.S. Kuehn, M. Radinger, J.M. Brown, K. Ali, B. Vanhaesebroeck, M.A. Beaven, D.D. Metcalfe, and A.M. Gilfillan J. Cell Sci. 123 2010 2576
7. S. Tsukada, D.J. Rawlings, and O.N. Witte Curr. Opin. Immunol. 6 1994 623
8. A.B. Satterthwaite, and O.N. Witte Immunol. Rev. 175 2000 120
9. B.J. Steinberg, P.A. Smathers, K. Frederiksen, and A.D. Steinberg J. Clin. Invest. 70 1982 587
10. L. Jansson, and R. Holmdahl Clin. Exp. Immunol. 94 1993 459
11. Z. Pan Drug News Perspect. 21 2008 357
12. E. Ruderman, and R.M. Pope Arthritis Res. Ther. 13 2011 125
13. R.W. Hendriks Nat. Chem. Biol. 7 2011 4
14. D. Xu, Y.K. Kim, J. Postelnek, M.D. Vu, D. Hu, C. Liao, M. Bradshaw, J. Hsu, J. Zhang, A. Pashine, D. Srinivassan, J. Woods, A. Levin, A. O'Mahony, T.D. Owens, Y. Lou, R.J. Hill, S. Narula, J. DeMartino, and J.S. Fine J. Pharmacol. Exp. Ther. 341 2012 90
15. C. Sheridan Nat. Biotechnol. 30 2012 199
16. Y. Lou, T.D. Owens, A. Kuglstatter, R.K. Kondru, and D.M. Goldstein J. Med. Chem. 55 2012 4539
17. S.E. Herman, A.L. Gordon, E. Herlein, A. Ramanunni, X. Zhang, S. Jaglowski, J. Flynn, J. Jones, K.A. Blum, J.J. Buggy, A. Hamdy, A.J. Johnson, and J.C. Byrd Blood 117 2011 6287
18. F. Cameron, and M. Sanford Drugs 74 2014 263
19. Currie, K.S.; Kropf, J.E.; Darrow, J.W.; Desimone, R.W. WO/2006/053121.
20. Currie, K.S.; Desimone, R.W.; Mitchell, S.A.; Pippin, D.A.I.; Darrow, J.W.; Qian, X.; Velleca, M.; Qian, D. US2006/0183746 A1.
21. L. Shewchuk, A. Hassel, B. Wisely, W. Rocque, W. Holmes, J. Veal, and L.F. Kuyper J. Med. Chem. 43 2000 133
22. Liu, Q.; Batt, G.D.; De Lucca, V.G.; Shi, Q.; Tebben, A. US8084620.
23. O.P.J. van Linden, A.J. Kooistra, R. Leurs, I.J.P. de Esch, and C. de Graaf J. Med. Chem. 57 2014 249
24. A.J. Di Paolo, T. Huang, M. Balazs, J. Barbosa, H.K. Barck, J.B. Bravo, A.D.R. Carano, J. Darrow, R.D. Davies, E.L. DeForge, L. Diehl, R. Ferrando, L.S. Gallion, M.A. Giannetti, P. Gribling, V. Hurez, G.S. Hymowitz, R. Jones, E.J. Kropf, P.W. Lee, M.P. Maciejewski, A.S. Mitchell, H. Rong, L.B. Staker, J.A. Whiteney, S. Yeh, B.W. Young, C. Yu, J. Zhang, K. Reif, and S.K. Currie Nat. Chem. Biol. 7 2011 41
25. Measure of IL-6 in Human Tonsilar B Cells: Human tonsilar B cells were isolated according to the general procedure of Gillooly et al. [Gillooly, K.M.; Pattoli, M.A.; Taylor, T.L.; Chen, L.; Cheng, L.; Gregor, K.R.; Whitney, G.S.; Susulic, V.; Watterson. S.H.; Kempson, J.; Pitts, W.J.; Booth-Lute, H.; Yang, G.; Davies, P.; Kukral, D.W.; Strnad, J.; McIntyre, K.W.; Darienzo, C.J.; Salter-Cid, L.; Yang, Z.; Wang-Iverson, D.B.; Burke, J.R. J. Pharmacol. Exp. Ther. 2009, 331, 349]. The isolated B cells were suspended in media containing 10% FBS and various concentrations of the testing compound. After a 1 h incubation at 37 °C, the cells were stimulated with 40 μg/mL F(ab′)2 goat anti-human IgM (Jackson ImmunoReasearch, cat# 109-006-129) and 10 ng/mL IL-4 (Peprotech, cat# 200-04). After an additional 4.5 h incubation, the supernatants were collected and the levels of IL-6 measured by EIA.
26. B.K. Wershil, Y.A. Mekori, T. Murakami, and S.J. Galli J. Immunol. 139 1987 2605